YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

August 30, 2028

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

YL-13027

YL-13027 is a small molecule inhibitor of the TGF-βRI target.

DRUG

HY-0102

HY-0102 is a recombinant anti-NKG2A humanized monoclonal antibody.

DRUG

Gemcitabine

Gemcitabine is a pyrimidine antineoplastic chemotherapeutic agent.

DRUG

Nab-paclitaxel

Paclitaxel for Injection (albumin bound) is a chemotherapeutic agent that acts as an antitumor agent by inhibiting tumor cell mitosis

All Listed Sponsors

lead

Shanghai YingLi Pharmaceutical Co. Ltd.

INDUSTRY

NCT06662669 - YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter